The issuance of equity funds witnessed a surge in September, with a total of 124 new funds entering the market. Among these, approximately 68% or 85 funds were equity-based products. Growth-oriented funds, particularly those focused on pharmaceuticals and high-end manufacturing, continued to dominate the issuance landscape. Additionally, several new floating-rate funds are set to follow suit in the coming period.
